Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL.
about
Targeting the Mitotic Catastrophe Signaling Pathway in CancerProlonged mitotic arrest triggers partial activation of apoptosis, resulting in DNA damage and p53 inductionDifferential determinants of cancer cell insensitivity to antimitotic drugs discriminated by a one-step cell imaging assayThe NOXA-MCL1-BIM axis defines lifespan on extended mitotic arrestABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21((CIP1/WAF1)) in human cancer cells.Synthesis of phenstatin/isocombretastatin-chalcone conjugates as potent tubulin polymerization inhibitors and mitochondrial apoptotic inducers.The proliferation rate paradox in antimitotic chemotherapy.MYC Is a Major Determinant of Mitotic Cell Fate.Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics.Carrageenan delays cell cycle progression in human cancer cells in vitro demonstrated by FUCCI imaging.Mitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survivalBcl-xL controls a switch between cell death modes during mitotic arrestLinking abnormal mitosis to the acquisition of DNA damageA simplified Bcl-2 network model reveals quantitative determinants of cell-to-cell variation in sensitivity to anti-mitotic chemotherapeutics.A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors.Kinesin spindle protein (KSP) inhibitors in combination with chemotherapeutic agents for cancer therapy.Targeting cell death signalling in cancer: minimising 'Collateral damage'.Cellular responses to a prolonged delay in mitosis are determined by a DNA damage response controlled by Bcl-2 family proteins.Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinicPhosphorylation of the proapoptotic BH3-only protein bid primes mitochondria for apoptosis during mitotic arrest.Post-slippage multinucleation renders cytotoxic variation in anti-mitotic drugs that target the microtubules or mitotic spindle.Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells.Inhibition of Bcl-xL sensitizes cells to mitotic blockers, but not mitotic drivers.Mcl-1 dynamics influence mitotic slippage and death in mitosis.Contribution of Bcl-2 phosphorylation to Bak binding and drug resistance.Prolonged mitotic arrest induces a caspase-dependent DNA damage response at telomeres that determines cell survivalDirect visualization of Bcl-2 family protein interactions using live cell fluorescent protein redistribution assays.ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cellsPhosphorylation of XIAP by CDK1-cyclin-B1 controls mitotic cell death.Oncogenic KRAS triggers MAPK-dependent errors in mitosis and MYC-dependent sensitivity to anti-mitotic agents.Is inflammatory micronucleation the key to a successful anti-mitotic cancer drug?Network dynamics-based cancer panel stratification for systemic prediction of anticancer drug response.Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers.Selective BCL-XL inhibition promotes apoptosis in combination with MLN8237 in medulloblastoma and pediatric glioblastoma cells.Mps1 Regulates Kinetochore-Microtubule Attachment Stability via the Ska Complex to Ensure Error-Free Chromosome Segregation.Perturbing mitosis for anti-cancer therapy: is cell death the only answer?Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.Universal response in the RKO colon cancer cell line to distinct antimitotic therapies.MYC-Induced miR-203b-3p and miR-203a-3p Control Bcl-xL Expression and Paclitaxel Sensitivity in Tumor Cells
P2860
Q26778544-BF9439B7-FE4D-49A9-93B7-81F3F519050BQ30505355-72AFB879-FD97-4757-8EA0-927C1E0DFF4CQ30546921-82D8CFB5-0EEC-4363-AAFB-099C9B1D1C49Q30648719-DF7CE061-7392-44B8-BE2B-2C0748DC0616Q33842714-F83D2655-6916-4141-A7BE-164E0623B7FBQ35568576-D94FF207-5E22-423E-89A6-3B6014CCF165Q35642841-12F7DAD7-6AA2-4C93-90CC-AA0E11CB3829Q35898987-EE57ECB9-536B-4FAF-B621-1B3C2BBB4927Q36026406-D651D585-9623-47CC-B0F3-EE7E30E47E6FQ36094147-50E50794-911B-4EC8-B9EB-CACAF893222CQ36104705-A15A4145-A107-4089-AACC-D75B4EEF2C18Q36179601-82D377DA-F20A-4DC1-8B42-3D67657A627BQ36455900-16353FFA-C355-499B-8FC3-1BB82ADC75A3Q37393924-7A1877FB-9EFE-4633-A6A0-FCE1A2308ADCQ37539213-5B2E8353-A59E-4E23-8ADE-F080C89FD125Q38130485-BE0EED48-9526-47A3-8B69-1B2885CDBF0EQ38824157-26D29092-90E5-48BF-AA0C-DDFA400BD55EQ38901065-32578551-A75A-484C-9E85-058DC4220EA8Q38935027-B82E9600-5BF9-4EE2-AD5E-B8A0C1648D3EQ39001169-D7F70182-BC6F-47B0-B86F-6B286AFC4D37Q39008852-59D99053-2693-495F-832A-93D575E97C36Q39360515-665F3089-E556-4B6D-A3EA-CAB0C7956FA6Q40994543-E7166ECC-0A5F-4169-A532-EF8612BB89E8Q41788107-FC1C443B-B58C-4B86-8DDA-32C820F7B754Q41906775-CF942EB2-5394-46EE-966D-B3A6AC1B0F9AQ41960771-6C28621E-B9D6-4B96-9E40-228A38F621BCQ41999376-AC1F43D1-E522-4056-99FF-CF0C4B045293Q42094231-66850FEC-4FAA-4E9C-88F5-AAE73C593EFCQ42113128-9F1C13A8-D91D-4E7F-B794-7D7C0E23266DQ42120891-C1FC50B9-739A-4926-A08A-752B936430A7Q47149120-272DEF3D-10CD-47AC-9113-C01A78EE2275Q47155414-21431B36-B399-4BE0-8E47-B037A6B260C6Q47368952-BC15CC59-4175-4E41-903B-2DA6DEB1445AQ47671054-5F3633B3-4067-4BA2-BBBF-E902E5F3F129Q48610746-DEB88778-990B-42B1-AAEC-F1315AA4392EQ49832249-514773EF-4C69-49EE-A445-FEFC54094E96Q53324308-0A2CEBE9-9662-4655-9906-6755C12293FAQ55312776-41B582D2-96F6-44BB-BE27-D4370F204C15Q57805991-1BFFF8AF-AF17-4F89-9FB3-4B0E3BD6AC4E
P2860
Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Navitoclax (ABT-263) accelerat ...... arrest by antagonizing Bcl-xL.
@ast
Navitoclax (ABT-263) accelerat ...... arrest by antagonizing Bcl-xL.
@en
type
label
Navitoclax (ABT-263) accelerat ...... arrest by antagonizing Bcl-xL.
@ast
Navitoclax (ABT-263) accelerat ...... arrest by antagonizing Bcl-xL.
@en
prefLabel
Navitoclax (ABT-263) accelerat ...... arrest by antagonizing Bcl-xL.
@ast
Navitoclax (ABT-263) accelerat ...... arrest by antagonizing Bcl-xL.
@en
P2093
P2860
P1433
P1476
Navitoclax (ABT-263) accelerat ...... arrest by antagonizing Bcl-xL
@en
P2093
Hsiao-Chun Huang
Timothy J Mitchison
P2860
P304
P356
10.1158/0008-5472.CAN-10-4336
P407
P50
P577
2011-05-05T00:00:00Z